On the stock market since 2010, it operates in the world of health and science. It has 73 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 51% below its peak. The market has trimmed its expectations for the company.
Sales run at $72.3M a year. A small number, but proof the product has real buyers.
There is $248.1M in the vault; even if every debt were paid off, $245.5M would remain.
The average analyst price target is $45.00 — 96% above today’s price.
A loss of $6.1M against $72.3M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 41/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, ASMB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ASMB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.